Bidya logo
  Crypto Coin Prices and News  

CTI Price   

Cap | Volume | High | Low | Old | New | Rare | Vs | Blockchains | Exchanges | Market | News | Dev News | Search | Watchlist

ClinTex CTi  


CTI Price:
$495.6 K
All Time High:
Market Cap:
$6.0 M

Circulating Supply:
Total Supply:
Max Supply:


The price of #CTI today is $0.031 USD.

The lowest CTI price for this period was $0, the highest was $0.031, and the exact current price of one CTI crypto coin is $0.03138.

The all-time high CTI coin price was $0.42.

Use our custom price calculator to see the hypothetical price of CTI with market cap of BTC or other crypto coins.


The code for ClinTex CTi crypto currency is #CTI.

ClinTex CTi is 2.3 years old.


The current market capitalization for ClinTex CTi is $6,003,443.

ClinTex CTi is ranking upwards to #650 out of all coins, by market cap (and other factors).


There is a medium daily trading volume on #CTI.

Today's 24-hour trading volume across all exchanges for ClinTex CTi is $495,638.


The circulating supply of CTI is 191,311,840 coins, which is 100% of the total coin supply.


CTI is a token on the Ethereum blockchain, and has digital contracts with 3 other blockchains.

See list of the CTI Blockchain contracts with 4 different blockchains.


CTI is available on several crypto currency exchanges.

View #CTI trading pairs and crypto exchanges that currently support #CTI purchase.



How AI will drive success in Clinical Trials

It takes up to 15 years and an average total R&D expenditure of $1.5–2 billion USD to bring a single new drug to market. About half of this investment is spent on clinical trials, with Phase III trials being the most complex and most expensive. Probabilities of success for compounds to proceed through the clinical trial stages vary from phase to phase, and lead to a situation where only 10% of compounds entering clinical trials advances to FDA approval. High clinical trial failure rates are one major cause for the prevailing inefficiency of the drug development cycle. Artificial intelligence (AI) has been a hot topic in the medical field for some time now. Some may view it as just another fad, but the truth is that AI has the potential to revolutionize the way we conduct clinical trials and discover new medicines. Two of the key factors causing a clinical trial to be unsuccessful are patient cohort selection and recruiting mechanisms which fail to bring the best suited patients to a trial in time. This potential financial loss is an incentive for pharmaceutical companies to use artificial intelligence (AI) technologies in the initial stages of clinical trials. AI technology can examine large amounts of data to detect patient subgroups that might benefit more in a clinical trial. It can also analyse social media content to identify specific regions where a condition is more prevalent, thus narrowing down the search for t...

ClinTex 2023 Roadmap

Over the past few weeks we have been meeting internally to define our strategy and goals in the runup to the new year. To this end we published the outline of our 2023 updated roadmap on the ClinTex homepage. Allow us a moment to briefly dive a little deeper into the next stages of the ClinTex plan. In 2023 ClinTex will focus on the development of indication-specific visuals and analytics to support clinical trials in the treatment of chronic pain. Q1 — Establish Core Packages to standardise and streamline analytics development using Optex technology. CTi to launch CTi Core Visualisations into Market. Via Optex, the CTi Visualisation Core will run completely decentralised, on-chain on top of the Internet Computer (ICP). Q2 — Development of visuals and analytics to directly support oversight of primary and secondary endpoints for a Phase III clinical trial for treatment of Chronic Pain. This is the final development sprint in preparation for go-to-market full live launch. Q3 — CTi Development Testing in a live trial environment. CTi Mainnet Quality Assurance Testing & User Acceptance Testing Q4 — Clintex CTi deployment in a live chronic pain clinical trials, including Clintex Data Management Consultancy Services (*). CTi Live Deployment including licencing mechanism — token CTi token utility goes live on client trial services, including token burn mechanism on licence expiry. *Consultanc...

ClinTex sign Letter of Intent with LVL Health

Clintex are excited to announce the signing of an agreement with LVL Health ( to support their CANPAIN clinical trial ( evaluating Cannabis Based Medicinal Products (CBMPs) in the treatment of Chronic Pain. This clinical trial is particularly high profile as it is being conducted to provide key data to NICE (National Institute for Care & Excellence) to prove the benefits of medical cannabis and enable prescription of CBMPs for chronic pain patients on the NHS. This therefore represents a major opportunity to showcase ClinTex CTi technology and demonstrate how it can help support accelerated patient access to much needed treatments. Previously Clintex, LVL Health and Celadon Pharmaceuticals have held a number of exploratory discussions and have arrived at a clear consensus on how the CTi platform and the clinical trial expertise at Clintex can support this high profile CANPAIN clinical trial. As a result, Clintex intend to provide certain services to LVL Health and the CANPAIN clinical trial including, but not limited to: Deployment of CTi through the creation and maintenance of CANPAIN specific data visuals to support oversight and instream insights into the main trial assessing CBMP for the treatment of non-cancer chronic pain, Consultancy on the data management strategy relating to the CANPAIN trial including liaising with Contract Research Organisations (CROs) and other vendors to o...

Q4–2022 at ClinTex HQ

The autumnal months have begun to set in here in Europe as the crypto bear market drags on, mirroring the wider global macro economic uncertainty that has been so evident thus far in 2022. To say it has been a tumultuous year so far would be an understatement, however here at ClinTex during our 9–5 working day we try not to let the market swings and roundabouts get us down nor affect our focus. The important thing, as we have learned from previous market cycles, is to stay fixed on our long term objectives. — Raydium LP - One of the emerging areas of crypto technology which we have been consistently impressed with this year has been the Solana blockchain. Although not without its teething problems, it is showing enormous promise by providing lightning fast transactions for fractions of a cent. This has brought with it the possibility to build highly efficient decentralized exchanges (DEXs) such as Raydium. We spoke on the launch of CTI2.0 about providing more potential cross-chain trading opportunities for our users and this one was high on our list for further investigation. We are now on track to have our Raydium liquidity pool online by the 15th of October. Details about how to trade on this new exchange once live will be posted here on Medium and as always, users can head into our official Telegram channel for more help if needed. — OpTex - One of the most important aspects of our production schedule over th...

ClinTex in discussions with Celadon Pharmaceuticals and LVL Health

We are extremely excited to announce that ClinTex are currently in active discussions with two ground breaking companies, to support clinical trials in the application of medicinal cannabis to manage chronic pain. Celadon Pharmaceuticals recently released a substantial business update since announcing to become the first British cannabis company since GW Pharmaceuticals to list on the Alternative Investments Market (AIM) in March of this year. Celadon became one of the first companies in the UK to receive a Home Office license to grow high-THC cannabis and as of May the company says it has now produced six batches at its 100,000 sq. ft facility in the Midlands. For more information on Celadon, see LVL Health is a leading medical cannabis clinic for chronic pain, providing a rapid access route to the highest quality treatment. Their clinicians prescribe medical cannabis as part of a patient’s pain management care after clinical assessments of safety and efficacy. Both companies have come together to initiate the CANPAIN clinical trial. This trial has been devised to evaluate the efficacy and safety of a defined cannabis-based medicinal product (CBMP) delivered by inhalation to patients with non-cancer chronic pain attending a private clinic. ClinTex have been working with both companies to evaluate the use of CTi to support this ground-breaking clinical trial and a number of areas of potential partnersh...

The Application of ClinTex CTi to accelerate approval of Cannabis Based Medicinal Products

Since 2018, when the UK Home Office announced that cannabis-based medicinal products (CBMPs) were to be moved from Schedule 1 to Schedule 2 status in the misuse of drugs regulations, ClinTex have been closely monitoring associated clinical trials which can help prove that these compounds possess untapped medical utility. One area where current scientific literature contains ample evidence for the successful application of medicinal cannabis are conditions relating to chronic, non-cancer pain. Chronic non-cancer pain is an oft-cited reason for patients who are already using cannabis for medical purposes. Collecting further data on the effectiveness and tolerability of medical cannabis is key in order to potentially pave the way for it’s approval as an NHS treatment in the future. The CANPAIN clinical trial being undertaken by LVL Health, will be a non-randomized, non-blinded real-world trial of the safety, tolerability and effectiveness of a CBMP for the treatment of chronic non-cancer pain compared against matched controls receiving standard of care pain management. The study could run for 3 years but there will be an interim analysis after 12 months with a planned sample size of at least 5000 participants per group, with each patient completing a minimum of 12-months treatment. The CBMP used will be an 8:8 (8% THC, 8% CBD) balanced flower delivered by steam inhalation using a handheld device with flow counting and Bluetoo...

CTi Q2 News and Progress report

A big hello to one and all out there in blockchain land, from ClinTex HQ! It’s been a busy year so far, as we approach the halfway point in 2022 already. Although it’s fair to say that this could possibly be referred in many ways to an annus horribilis for the crypto space, with the disastrous collapse of UST and Luna and the contagion of the wider macro economic outlook breathing heavily down the neck of all things blockchain related. In times like this we wish to remind our community and all those who are more than just casual observers in the world of crypto, to try not to focus on crashing valuations or prices, difficult as this may sound. Very little has changed from a fundamental point of view, over the last 6–12 months, when it comes to the longer term view of projects like ClinTex. As we have all come to learn in the blockchain arena, wild price fluctuations are par for the course, both to the upside and unfortunately in times like these, to the downside too. What might bring solace however is trying to remember why you found a particular project appealing in the first place, focusing on the goals that a project is trying to achieve or overcome. Little if anything has changed in this regard and work towards these goals continues, even as prices plummet, we continue to strive towards our stated objectives. We are very proud to announce that we have been making serious headway in bringing the ClinTex CTi toolset o...

CTI2.0 is LIVE!

The date has finally arrived! We are delighted to announce that $CTI token has been officially upgraded to a sleeker, more efficient, more decentralized and cross-chain compatible iteration — $CTI2.0 The official new CTI2.0 Ethereum Contract ID is : 0xcB8fb2438A805664cD8c3e640b85AC473DA5BE87 The official new CTI2.0 on Solana Contract ID is : 9ET2QCQJdFkeKkuaampNbmicbA8eLYauFCWch9Ddh9p5 The official new CTI2.0 on Polygon Contract ID is : 0x03c2f6808502ffd4ab2787ad1a98ec13dbd5718b The official new CTI2.0 on BSC Contract ID is : 0x7C3B67B30eFBAcC8f787f7EBd3bdc65234299f4c Both of our partner exchanges, KuCoin and have successfully made the switchover. If you held CTI on either exchange, you are now already in possession of the new token and trading on either exchange continues as normal, no need to do anything. It is VERY important that you do NOT send old CTI tokens to the exchange anymore as this may result in lost tokens! If you hold CTI tokens in a self custodied Ethereum wallet, you must exchange them for CTI2.0 manually via our swap portal here : Please note that the swap portal currently only ...

CTI2.0 is Launching

As you may well be aware, it’s been a while in the works, but we’re delighted to announce that we’re finally there, CTI2.0 is ready for action! After many weeks and in the end, months of designing, building, testing and re-building, we are now confident that we have the contract we require for all ClinTex stakeholders, our community, future clients and partner exchanges. The time has come to upgrade our smart contract offering and we can’t wait to get started! Our new contract will launch on May 10th 2022 — and with this, CTi will officially become a cross-chain tokenAs a CTI token holder, what do I need to do now? The simplest, cheapest and easiest method to swap your tokens will be by depositing them on one of our partner exchanges who shall be supporting the upgrade, namely KuCoin or If you already hold your CTI tokens on either of these exchanges then you don’t need to do anything, on the upgrade day your tokens will automatically be converted to the new contract. If you hold your tokens outside of the exchanges in self-custody, ClinTex will provide a swap portal on which will facilitate the process quickly and easily using Metamask or any web3 wallet. Note: While we have optimised the swap contract to use the minimal amount of gas possible, as the process is taking place on-chain there will be a gas fee as is standard on the Ethereum blockchain. This is by-passed if your toke...

March 2022 Development Update

Hello to all out there in the ClinTex community and welcome to our latest update for March of 2022. Sadly it appears the strange times have seemingly continued into the new year and it is with a heavy heart that we are witnessing the developments unfolding in Ukraine. Our sincerest thoughts and prayers go out to all of those affected and we strongly wish for a swift resolution that will bring peace and an end to the current conflict. Things here at ClinTex have been progressing full steam ahead, with CTi-PDA, the second in our suite of 7 analytics tools now having reached alpha stage. This month’s update will give you all an early sneak peak into how PDA works from a client point of view, progress reports on OpTex, CTi 2.0 and also some very exciting news regarding a partnership with a very promising project which we have been liaising with over the past few months, Plethori. We are also running a small competition to help expand and grow the ClinTex community and you can be in with a chance to win some free CTI tokens if you take part! Take a look towards the end of this update for more info on how to get involved! CTI-PDA The development team have done a great job in driving forward the delivery of this innovative app within the Clintex CTi suite of tools, with a number of iterations of early stage development now complete and rigorous testing underway. We are now working off version 52 of the CTi tool as our production c...

CTI vs MANA | A-Z | Topics | ISO 20022

Privacy | Terms | Contact | Powered By LiveCoinWatch